Walmart Shares Rise as UBS Lifts Price Target

UBS has raised its price target on Walmart Inc. (WMT) to $135 from $122, maintaining a Buy rating as the retail giant doubles down on its healthcare ambitions with significant investments in pharmacy workforce compensation and expanded roles.

Walmart Price Target Raised at UBS

Walmart shares traded at $117.72 on Friday morning, up $0.31 or 0.26% from the previous close, though well below the newly established $135 price target. The stock opened at $116.91 and fluctuated between an intraday low of $116.61 and a high of $117.845 on volume of 2.66 million shares by mid-morning Pacific time. The UBS upgrade represents approximately 14.7% upside potential from current levels, signaling renewed confidence in the company’s strategic direction despite broader market uncertainty.

Core Details

The analyst upgrade comes on the heels of Walmart’s announcement that it is elevating 3,000 pharmacy technician positions to pharmacy operations team lead roles, a move that underscores the retailer’s commitment to building out its Health & Wellness division. These newly created positions offer an average hourly wage of $28, with top earners potentially reaching $42 per hour—a substantial increase that positions Walmart competitively in the healthcare labor market.

Beyond the leadership promotions, Walmart is also expanding compensation ranges for existing pharmacy technicians, who previously earned an average of $22 per hour. Under the new structure, these associates can now earn up to $40.50 per hour, representing a potential increase of more than 84% for top performers. Notably, none of these positions require a college degree, and Walmart provides financial support for associates seeking pharmacy technician certification.

The wage enhancements are part of a broader healthcare expansion strategy that includes digital pharmacy services, participation in Eli Lilly’s LillyDirect program for direct-to-consumer prescription delivery, and enhanced pharmacy delivery options across Walmart’s 4,600 locations nationwide. This infrastructure investment aims to strengthen local pharmacy teams while providing customers with more accessible healthcare solutions at a time when traditional healthcare costs continue to rise.

Strategic Context

According to Walmart’s official corporate statement, the company views these investments as essential to maintaining its competitive edge in the rapidly evolving healthcare retail space. The announcement comes as major retailers increasingly compete for healthcare market share, with Amazon, CVS, and Walgreens all expanding their own pharmacy and telehealth offerings.

The timing of UBS’s price target increase suggests analysts view Walmart’s healthcare investments as value-accretive rather than margin-dilutive. By elevating wages and creating career pathways without degree requirements, Walmart addresses two critical challenges simultaneously: attracting and retaining qualified pharmacy staff in a tight labor market, and building customer loyalty through improved service quality and accessibility.

Walmart Outlook and Analysis

The $13 price target increase from UBS reflects growing confidence that Walmart’s healthcare initiatives will translate into measurable revenue growth and market share gains. With pharmacy services representing a high-frequency touchpoint for customers, improved staffing and compensation could drive increased foot traffic and cross-selling opportunities across Walmart’s broader retail ecosystem.

Markets appear cautiously optimistic about the healthcare push, though the modest Friday morning price movement suggests investors are waiting for concrete financial results before fully pricing in the UBS target. The gap between current trading levels and the $135 target indicates either skepticism about execution risks or broader macroeconomic concerns tempering enthusiasm for retail equities.

From a technical perspective, the stock’s ability to hold above the $116 level while digesting the news suggests underlying support, though breaking through resistance in the $118-$120 range will likely require additional catalysts or stronger-than-expected quarterly results demonstrating return on the healthcare investments.

WMT Closing Assessment

Walmart’s decision to invest heavily in pharmacy workforce development represents a calculated bet that healthcare services will drive long-term customer loyalty and revenue diversification, earning it a vote of confidence from UBS analysts. However, the market’s muted immediate response highlights lingering questions about execution timelines, competitive pressures, and whether wage increases will meaningfully impact profitability in the near term. The path to UBS’s $135 target will depend on Walmart’s ability to convert these workforce investments into measurable healthcare market share gains while maintaining the operational efficiency that has historically defined its success.

Walmart Analyst Summary